MedImmune FluMist Manufacturing Violations Cited In FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA also issued a “complete response” letter for MedImmune’s sBLA for the vaccine in younger children as a result of the compliance issues.
You may also be interested in...
MedImmune’s FluMist Approved For Children As Young As Age Two
Firm will begin shipments immediately to make doses available for the 2007-2008 influenza season.
MedImmune’s FluMist Approved For Children As Young As Age Two
Firm will begin shipments immediately to make doses available for the 2007-2008 influenza season.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.